QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Achieve Life Sciences Stock Price, News & Analysis (NASDAQ:ACHV)

$5.79
+0.07 (+1.22%)
(As of 11/30/2023 ET)
Compare
Today's Range
$5.70
$5.87
50-Day Range
$3.65
$5.86
52-Week Range
$2.36
$10.30
Volume
9,395 shs
Average Volume
101,069 shs
Market Capitalization
$122.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

Achieve Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.4% Upside
$18.67 Price Target
Short Interest
Bearish
3.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.27mentions of Achieve Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.57) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

719th out of 949 stocks

Diagnostic Substances Industry

9th out of 13 stocks


ACHV stock logo

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

ACHV Stock Price History

ACHV Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
ACHV: Ancillary Studies Complete
Q3 2023 Achieve Life Sciences Inc Earnings Call
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
The Achieve Foundation Newstead 5K is Saturday, September 30
ACHV: 2Q:23 Results
Q2 2023 Achieve Life Sciences Inc Earnings Call
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/16/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.67
High Stock Price Target
$20.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+222.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.19 per share

Miscellaneous

Free Float
20,743,000
Market Cap
$122.57 million
Optionable
Not Optionable
Beta
1.44
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Richard A. B. Stewart (Age 64)
    Executive Chairman
    Comp: $575k
  • Mr. John A. Bencich M.B.A. (Age 46)
    CEO & Director
    Comp: $733.12k
  • Dr. Cindy Jacobs M.D. (Age 65)
    Ph.D., President, Chief Medical Officer & Director
    Comp: $614.25k
  • Mr. Jerry Wan (Age 41)
    Principal Accounting Officer
  • Dr. Anthony Clarke (Age 67)
    Chief Scientific Officer
    Comp: $546k
  • Ms. Jaime Xinos
    Executive Vice President of Commercial














ACHV Stock Analysis - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price target for 2024?

2 analysts have issued 12-month price objectives for Achieve Life Sciences' stock. Their ACHV share price targets range from $17.00 to $20.00. On average, they predict the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 222.4% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How have ACHV shares performed in 2023?

Achieve Life Sciences' stock was trading at $2.45 at the beginning of 2023. Since then, ACHV shares have increased by 136.3% and is now trading at $5.79.
View the best growth stocks for 2023 here
.

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ACHV earnings forecast
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same period in the previous year, the business earned ($0.76) EPS.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences's stock reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include LPL Financial LLC (0.78%), Raymond James & Associates (0.69%), Northern Trust Corp (0.37%), Manchester Financial Inc. (0.09%), Group One Trading L.P. (0.00%) and Belvedere Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACHV) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -